Soligenix Reports Positive Extended Phase 2a Results for Psoriasis Treatment SGX302
TL;DR
Soligenix's SGX302 gel shows superior efficacy over its ointment formulation in psoriasis trials, offering investors a potential advantage in the rare disease treatment market.
Soligenix's Phase 2a trial demonstrated SGX302's optimized topical gel formulation improved clinical scores and quality-of-life measures with no drug-related adverse events.
SGX302's non-carcinogenic, non-mutagenic properties could provide a safer therapeutic option for psoriasis patients, improving treatment outcomes and quality of life.
Soligenix's synthetic hypericin gel for psoriasis shows promising results, potentially offering a novel, non-toxic treatment derived from a natural compound.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix Inc. reported extended results from its ongoing Phase 2a trial evaluating SGX302 for mild-to-moderate psoriasis, including outcomes from an additional cohort treated with an optimized topical gel formulation. The gel demonstrated improvements across multiple clinical and quality-of-life measures, with results comparable to or exceeding those observed with the prior ointment formulation. The extended Phase 2a results showed the gel was well tolerated with no drug-related adverse events. Clinical measures included Investigator Global Assessment and Psoriasis Area and Severity Index scores, both showing meaningful improvement. These findings support continued development of SGX302 as a potential non-carcinogenic, non-mutagenic therapeutic option for psoriasis patients.
SGX302 contains synthetic hypericin, the same active ingredient being developed in the company's HyBryte treatment for cutaneous T-cell lymphoma. The company's Specialized BioTherapeutics business segment is developing synthetic hypericin for multiple indications, with regulatory approvals being sought worldwide following successful Phase 3 studies. More information about the company's development programs is available at https://nnw.fm/SNGX. The positive extended results come as Soligenix continues to advance its pipeline of treatments for rare diseases with unmet medical needs. The company's development programs include expansion of synthetic hypericin into psoriasis, first-in-class innate defense regulator technology for inflammatory diseases, and multiple vaccine candidates.
The Public Health Solutions business segment has been supported with government funding from agencies including the National Institute of Allergy and Infectious Diseases. These extended Phase 2a results represent an important step in developing SGX302 as a potential new treatment option for psoriasis patients. The optimized gel formulation's performance, combined with the favorable safety profile, provides a foundation for further clinical development. The full press release detailing these results can be accessed at https://nnw.fm/9ngJA.
Curated from InvestorBrandNetwork (IBN)
